glp 1 drugs heart failure GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes Bridging the gap between GLP1-receptor

Finerenone in heart failure with mildly reduced or preserved ejection fraction

Phase 3 trials are the final and most in-depth study phase before a drug is approved for treatment

Unlike Zepbound and Mounjaro, it is not FDA approved and is unlikely to be covered by insurance

The first GLP-1 drugs developed are self-administered via daily or weekly subcutaneous (under the skin) injections using a pre-filled pen

A GLP-1 Receptor Agonist Liraglutide Inhibits Endothelial Cell Dysfunction and Vascular Adhesion Molecule Expression in an ApoE-/- Mouse Model

Experts from UT Southwestern, University of Colorado, Cato Institute, and Obesity Action Coalition share what evidence currently shows about GLP-1 function and effectiveness and discuss how to ensure patient access, affordability, and safety